Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0980720160350010073
Keimyung Medical Journal
2016 Volume.35 No. 1 p.73 ~ p.78
Intractable in Stent Thrombosis in Malignant Superior Vena Cava Syndrome
Lee Sang-Ho

Shim Chang-Woo
Chi Ho-Seok
Lee Hye-In
Choi Do-Il
Kim Heung-Tae
Kim Hyun-Boem
Lee In-Joon
Kim Sun-Young
Abstract
Endovascular treatment (EVT) including angioplasty and stenting is an effective treatment for superior vena cava (SVC) syndrome. Recurrence of SVC syndrome is mainly caused by tumor progression and occurs in around 20% after EVT, but sometimes venous thrombosis within stent accounts for recurrence of SVC syndrome. Anticoagulation after EVT is still a
controversial issue. In our case, a 73-year-old man with SVC syndrome caused by mediastinal metastasis from non-small cell lung cancer underwent endovascular stent followed by anticoagulation with low molecular weight heparin (LMWH), but symptomatic progression due to in-stent thrombosis necessitated the second procedure after two weeks. A
total of 4 sessions of endovascular stent and anticoagulation with LMWH, warfarin and rivaroxaban did not induce durable resolution of in-stent thrombosis. Our case suggests refractory in-stent thrombosis could develop despite of anticoagulation after endovascular stent for SVC syndrome.
KEYWORD
Anticoagulation, Endovascular treatment, Superior vena cava syndrome
FullTexts / Linksout information
 
Listed journal information